UroGen Pharma Ltd. Ordinary Shares Stock Prediction
AI-powered sentiment analysis and prediction trends for URGN, updated each market day.
URGN AI Sentiment
AI predicts UroGen Pharma Ltd. Ordinary Shares stock is likely to decrease over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About UroGen Pharma Ltd. Ordinary Shares
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.
Sector
Exchange
Market Cap
$999,447,208
Cap Tier
Employees
291
Headquarters
RA'ANANA, L3
Listed Since
May 4, 2017
Website
URGN Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
URGN Volatility
UroGen Pharma Ltd. Ordinary Shares has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
